Donor pretreatment with ambroxol or dexamethasone fails to ameliorate reperfusion injury in experimental lung transplantation.
Based on the known properties of ambroxol and dexamethasone to inhibit inflammation and increase endogenous surfactant levels, the potential advantage of donor pretreatment with either drug was investigated in an acute rat double-lung transplant model. Donor animals were randomly assigned to one of three treatment groups: an ambroxol group (AMB; 0.4 mg/kg), a dexamethasone group (DX; 2 mg/kg); or an untreated control group (CN). Drugs were given intraperitoneally 6 h prior to harvest. Following standard preservation and 16 h of cold ischemia, the donor double lung block was implanted into syngeneic recipients using custom-designed stents for the vascular anastomosis. During reperfusion, serial measurements of graft pulmonary vascular resistance and alveolar-arterial oxygen difference were obtained. Separate graft ventilation allowed determination of graft dynamic lung compliance. Final assessment included weight gain and histology. For phospholipid analysis, lung lavages were performed in the three study groups at the end of reperfusion and compared to levels before graft harvest. Donor pretreatment did not significantly affect preharvest phospholipid levels. Survival following graft ischemia and reperfusion was shortest after AMB (92 +/- 5 min) and longest after DX (110 +/- 5 min; DX vs AMB P < 0.03) and CN (116 +/- 4 min; CN vs AMB P < 0.02). DX pretreatment provided better compliance (P < 0.02) and lower vascular resistance (P < 0.0001) than AMB treatment. Airway resistance was lower in the AMB and DX groups than in controls (P < 0.04 and P < 0.02, respectively). The alveolar-arterial oxygen difference was markedly similar in all groups. Graft weight gain amounted to 114% +/- 10% in AMB, 88% +/- 12% in DX, and 98% +/- 13% in CN (P = NS). Thus, in this rat lung transplantation model, donor pretreatment with dexamethasone did not improve graft function compared to untreated controls and donor pretreatment with ambroxol was found to be potentially detrimental to graft function during reperfusion.
Hausen
B
B
Department of Cardiothoracic Surgery, Stanford University Medical Center, CA 94304-5407, USA. hausen@leland.stanford.edu
Bahra
M
M
Mueller
P
P
Poets
C F
CF
Hewitt
C W
CW
Morris
R E
RE
D000551:Ambroxol / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D003907:Dexamethasone / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005100:Expectorants / Q000627:therapeutic use*; D016040:Lung Transplantation / Q000473:pathology*; D010743:Phospholipids / Q000032:analysis; D011650:Pulmonary Alveoli / Q000378:metabolism; D011652:Pulmonary Circulation; D011663:Pulmonary Surfactants / Q000378:metabolism; D051381:Rats; D015427:Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D019172:Transplantation Conditioning / Q000379:methods*
D000893:Anti-Inflammatory Agents; D005100:Expectorants; D010743:Phospholipids; D011663:Pulmonary Surfactants; D000551:Ambroxol; D003907:Dexamethasone